Table 5.

Prognostic Effects of Progesterone-Receptor Status in Women with Metachronous Breast Cancers, SEER 1998-2011

	Overall Survival
Progesterone-receptor status	No. of patients	No. of patients at year 5	No. of events	Rate^a	Model 1, HR (95% CI)^b		Model 2, HR (95% CI)^c
Progesterone-receptor status	No. of patients	No. of patients at year 5	No. of events	Rate^a	≤ 5 years	> 5 years	≤ 5 years	> 5 years

+/+	2835	952	486	4.3	1.0 (ref)	1.0 (ref)	1.0 (ref)	1.0 (ref)
−/+	1142	336	202	4.8	0.88 (0.69-1.12)	0.97 (0.63-1.48)	1.04 (0.77-1.40)	1.56 (0.90-2.72)
+/−	1741	542	369	5.4	1.33 (1.10-1.60)	0.70 (0.47-1.04)	1.24 (1.00-1.54)	0.77 (0.49-1.21)
−/−	1441	426	405	7.6	1.44 (1.18-1.77)	0.59 (0.37-0.92)	1.24 (0.94-1.65)	0.94 (0.50-1.77)
P value					<0.0001	0.06	0.21	0.19

	Breast Cancer-Specific Survival
Progesterone-receptor status	No. of patients	No. of patients at year 5	No. of events	Rate^a	Model 1, HR (95% CI)^b		Model 2, HR (95% CI)^c
Progesterone-receptor status	No. of patients	No. of patients at year 5	No. of events	Rate^a	≤ 5 years	> 5 years	≤ 5 years	> 5 years

+/+	2835	952	203	1.8	1.0 (ref)	1.0 (ref)	1.0 (ref)	1.0 (ref)
−/+	1142	336	100	2.4	0.95 (0.67-1.35)	1.05 (0.54-2.02)	1.32 (0.86-2.01)	1.52 (0.61-3.75)
+/−	1741	542	222	3.3	1.56 (1.19-2.04)	0.66 (0.35-1.23)	1.44 (1.06-1.96)	0.82 (0.40-1.69)
−/−	1441	426	310	5.9	1.59 (1.21-2.10)	0.53 (0.27-1.02)	1.47 (1.01-2.14)	0.62 (0.21-1.84)
P value					<0.0002	0.17	0.11	0.45

Abbreviations: HR, hazard ratio; CI, confidence interval

Death rate per 100 person-years

Adjusted in a piecewise Cox model for age at diagnosis, race/ethnicity, marital status, AJCC stage of both cancers, histology of both cancers, surgery type of both cancers, radiotherapy of both cancers, and time interval between the two cancers

Adjusted for estrogen-receptor status of the two cancers and all variables in Model 1

P value is from the omnibus test of comparing four groups in the Cox model